Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Nov 10, 2022 12:11pm
155 Views
Post# 35088771

RE:RE:RE:How the heck….

RE:RE:RE:How the heck….MM - your math is always impeccable so I'm sure it's correct.  They did say the upcoming flu season - expected to be very pervasive - will provide the required cases in the trial sites.  And 42 isn't a big number in the context of 14 and then 18 sites.  Flu season will produce enough cases (look at Australia) and I expect GREED will capture them pronto for Tigris.

More interesting is what the undisclosed change to the Interim Deal is with Baxter.  The US$2.5 mill of convertible paper became an adjustment to that part of the deal.  NO DISCLOSURE - that is shameful from a governance perspective.  Especially since lots of them loaded up disproportionately to past participation from this equity issue.
<< Previous
Bullboard Posts
Next >>